ATE550032T1 - Verwendung von glp-1, exendin und agonisten davon zur verzögerung oder verhinderung von kardialer remodellierung - Google Patents

Verwendung von glp-1, exendin und agonisten davon zur verzögerung oder verhinderung von kardialer remodellierung

Info

Publication number: ATE550032T1
Authority: AT; Austria
Prior art keywords: exendin; glp; agonists; delay; prevent
Prior art date: 2005-04-11

Application number

AT06740942T

Other languages

English (en)

Inventor

Christen Anderson

Que Liu

Original Assignee

Amylin Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-11

Filing date

2006-04-11

Publication date

2012-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36926409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE550032(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-04-11 Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc

2012-04-15 Application granted granted Critical

2012-04-15 Publication of ATE550032T1 publication Critical patent/ATE550032T1/de

Links

238000007634 remodeling Methods 0.000 title abstract 3
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title abstract 2
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title abstract 2
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
239000000556 agonist Substances 0.000 title abstract 2
230000000747 cardiac effect Effects 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
206010019280 Heart failures Diseases 0.000 abstract 1
230000003293 cardioprotective effect Effects 0.000 abstract 1
MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AT06740942T 2005-04-11 2006-04-11 Verwendung von glp-1, exendin und agonisten davon zur verzögerung oder verhinderung von kardialer remodellierung ATE550032T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US66987605P	2005-04-11	2005-04-11
PCT/US2006/013949 WO2006110887A2 (en)	2005-04-11	2006-04-11	Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling

Publications (1)

Publication Number	Publication Date
ATE550032T1 true ATE550032T1 (de)	2012-04-15

Family

ID=36926409

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06740942T ATE550032T1 (de)	2005-04-11	2006-04-11	Verwendung von glp-1, exendin und agonisten davon zur verzögerung oder verhinderung von kardialer remodellierung

Country Status (5)

Country	Link
US (1)	US8946149B2 (de)
EP (1)	EP1888103B1 (de)
AT (1)	ATE550032T1 (de)
DK (1)	DK1888103T3 (de)
WO (1)	WO2006110887A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2425738T3 (es)	2001-12-21	2013-10-17	Human Genome Sciences, Inc.	Proteínas de fusión de la albúmina
EP1729795B1 (de)	2004-02-09	2016-02-03	Human Genome Sciences, Inc.	Albuminfusionsproteine
KR20090031368A (ko)	2006-05-26	2009-03-25	아밀린 파마슈티칼스, 인크.	울혈성 심부전 치료용 조성물 및 방법
PL2373681T3 (pl)	2008-12-10	2017-07-31	Glaxosmithkline Llc	Kompozycje farmaceutyczne albiglutydu
WO2011140176A1 (en)	2010-05-04	2011-11-10	Glaxosmithkline Llc	Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG10201705097PA (en)	2012-12-21	2017-07-28	Sanofi Sa	Functionalized exendin-4 derivatives
EP3080149A1 (de)	2013-12-13	2016-10-19	Sanofi	Duale glp-1-/glucagon-rezeptoragonisten
WO2015086729A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/gip receptor agonists
TW201609795A (zh)	2013-12-13	2016-03-16	賽諾菲公司	作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
MX391259B (es)	2015-10-14	2025-03-21	X Therma Inc	Composiciones y métodos para reducir la formación de cristales de hielo.
EP3875476A4 (de) *	2018-10-30	2022-08-24	Jianning Liu	Glp-1-polypeptid mit glp-1-rezeptor-agonistenaktivität und dessen verwendungen
TW202228762A (zh) *	2020-01-30	2022-08-01	美商美國禮來大藥廠	提派肽(tirzepatide)之治療用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4554101A (en)	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5118666A (en)	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
DE69129226T2 (de)	1990-01-24	1998-07-30	Douglas I. Woodside Calif. Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
DK1019077T4 (da) *	1997-08-08	2011-03-07	Amylin Pharmaceuticals Inc	Hidtil ukendte exendinagonistforbindelser
AU756836B2 (en)	1997-11-14	2003-01-23	Amylin Pharmaceuticals, Inc.	Novel exendin agonist compounds
WO1999025727A2 (en)	1997-11-14	1999-05-27	Amylin Pharmaceuticals, Inc.	Novel exendin agonist compounds
ATE366115T1 (de)	1998-02-13	2007-07-15	Amylin Pharmaceuticals Inc	Inotropische und diuretische effekte von exendin und glp-1
US6703359B1 (en)	1998-02-13	2004-03-09	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and GLP-1
US6284725B1 (en)	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
AU2001254621A1 (en)	2000-05-05	2001-11-20	K.U. Leuven R And D	Critical illness neuropathy
WO2001089554A2 (en)	2000-05-19	2001-11-29	Bionebraska, Inc.	Treatment of acute coronary syndrome with glp-1
WO2002034285A2 (en)	2000-10-20	2002-05-02	Coolidge Thomas R	Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
EP1390061A2 (de)	2000-12-13	2004-02-25	Eli Lilly And Company	Chronisches behandlungsverfahren unter verwendung von glukagon-ähnlichen insulinotropischen peptiden
CA2458371A1 (en)	2001-08-23	2003-03-06	Eli Lilly And Company	Glucagon-like peptide-1 analogs
US20030199445A1 (en)	2002-02-07	2003-10-23	Knudsen Lotte Bjerre	Use of GLP-1 compound for treatment of critically ill patients
JP2005535569A (ja)	2002-04-04	2005-11-24	ノボ・ノルデイスク・エー／エス	Ｇｌｐ−１アゴニスト及び心臓血管合併症
WO2004035762A2 (en)	2002-10-17	2004-04-29	Alkermes Controlled Therapeutics, Inc. Ii	Microencapsulation and sustained release of biologically active polypeptides
US7192922B2 (en)	2002-11-19	2007-03-20	Allegheny-Singer Research Institute	Method of treating left ventricular dysfunction
US7186692B2 (en)	2002-12-17	2007-03-06	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7790681B2 (en)	2002-12-17	2010-09-07	Amylin Pharmaceuticals, Inc.	Treatment of cardiac arrhythmias with GLP-1 receptor ligands
EP1610811A4 (de)	2002-12-17	2008-03-26	Amylin Pharmaceuticals Inc	Vorbeugung und behandlung von herzrhythmusstörungen
ES2425221T3 (es)	2003-05-30	2013-10-14	Amylin Pharmaceuticals, Llc	Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
CA2528465A1 (en)	2003-06-09	2005-01-20	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of growth hormone
WO2005060986A1 (en)	2003-12-12	2005-07-07	Albert Einstein College Of Medicine Of Yeshiva University	Glp-1 (9-36) methods and compositions
AU2005323063B2 (en)	2004-12-24	2011-01-27	Amylin Pharmaceuticals, Llc	Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosis
KR20090031368A (ko) *	2006-05-26	2009-03-25	아밀린 파마슈티칼스, 인크.	울혈성 심부전 치료용 조성물 및 방법

2006
- 2006-04-11 US US11/910,730 patent/US8946149B2/en active Active
- 2006-04-11 WO PCT/US2006/013949 patent/WO2006110887A2/en not_active Ceased
- 2006-04-11 EP EP06740942A patent/EP1888103B1/de not_active Not-in-force
- 2006-04-11 AT AT06740942T patent/ATE550032T1/de active
- 2006-04-11 DK DK06740942.5T patent/DK1888103T3/da active

Also Published As

Publication number	Publication date
US20090137466A1 (en)	2009-05-28
EP1888103B1 (de)	2012-03-21
WO2006110887A2 (en)	2006-10-19
WO2006110887A3 (en)	2007-03-22
US8946149B2 (en)	2015-02-03
DK1888103T3 (da)	2012-04-23
EP1888103A2 (de)	2008-02-20

Publication	Publication Date	Title
ATE550032T1 (de)	2012-04-15	Verwendung von glp-1, exendin und agonisten davon zur verzögerung oder verhinderung von kardialer remodellierung
JOP20220024A1 (ar)	2023-01-30	مركبات مساعدة لـ gipr
DK2358717T3 (da)	2013-11-18	Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes
SA521431209B1 (ar)	2024-08-05	مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
NO20070487L (no)	2007-03-05	3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO331089B1 (no)	2011-10-03	Sammensetning omfattende en GPR119-agonist og en DPP-IV-inhibitor samt fremgangsmate for fremstilling av slike.
EA201791281A1 (ru)	2017-11-30	Соединения-коагонисты гип и гпп-1
ECSP077180A (es)	2007-04-26	Compuestos, composiciones y métodos
WO2008019147A3 (en)	2009-06-11	Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
NO20072223L (no)	2007-06-25	Glykogenfosforylaseinhibitor forbindelser med farmsoytiske preparater av disse
EA201391236A1 (ru)	2014-01-30	Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
EA201101187A1 (ru)	2012-10-30	Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
EP3765086C0 (de)	2025-01-08	Zusammensetzung, die die konzentration von nicotinamid-adenin-dinucleotid (nad) beeinflusst, zur minderung der auswirkungen des alters
EA201300583A1 (ru)	2013-12-30	Вазопротективное и кардиопротективное противодиабетическое лечение
NO20092651L (no)	2009-09-14	Dihydropyridinderivater som er anvendelige som proteinkinaseinhibitorer
EP3922260A3 (de)	2022-06-15	Insulinrezeptorteilagonisten und glp-1-analoga
BR112012010762A2 (pt)	2018-03-20	inibidores de prolil hidroxilalse
NO20084278L (no)	2008-10-30	Bezothiazol derivatives as beta2 adrenoreceptor agonists
NO20091596L (no)	2009-06-30	Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
WO2007070434A3 (en)	2008-03-06	Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
EA201000515A1 (ru)	2010-10-29	Активаторы глюкокиназы
MX2025009636A (es)	2025-11-03	Agonistas heterocíclicos de glp-1
CL2007000595A1 (es)	2008-01-04	Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
WO2007062028A8 (en)	2008-05-15	Treatment of qt interval prolongation and diseases associated therewith
PH12020551076A1 (en)	2021-08-16	Methods for treating diabetes, hepatitis, and/or inflammatory liver disease